BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies,...
BioCentury | Mar 14, 2020
Emerging Company Profile

Indapta harnesses natural NK cell subset to create allogeneic cancer therapy

Indapta is sidestepping genome engineering for its universal NK cells, a strategy that not only reduces manufacturing costs but also broadens the number of cancer patients it could treat relative to genetically edited allogeneic NK...
BioCentury | Aug 16, 2017
Distillery Techniques


TECHNOLOGY: Gene profiling A profile containing a nine-gene signature in tumors and FCER1B protein levels in tumor mast cells could help predict survival in lung cancer. In 1,225 non-small cell lung cancer (NSCLC) patients, transcriptomic...
BioCentury | Feb 22, 2017
Distillery Techniques

Drug delivery

...binding between IgE and Fc fragment of IgE high affinity I receptor for α polypeptide (FCER1A... Jan. 14, 2017 doi:10.1016/j.xphs.2017.01.002 CONTACT: H. Arima, Kumamoto University, Kumamoto, Japan email: Hongjiang Li Lucentis Synagis Vectibix Xolair Kumamoto University Fc fragment of IgE high affinity I receptor for alpha polypeptide (FCER1A) Immunoglobulin...
BioCentury | Dec 20, 2016
Distillery Therapeutics

Dermatology; inflammation

INDICATION: Dermatitis; allergy Cell culture and mouse studies suggest morpholino oligomers that exclude exon 3 from the FCER1B transcript could help treat allergy and allergic dermatitis. In activated primary mouse bone marrow-derived mast cells, a...
BioCentury | Oct 29, 2015
Distillery Therapeutics

Therapeutics: Interleukin-9 (IL-9); (FCER1A)

...IgE and histamine, and diarrhea compared with vehicle challenge. In the mouse model, an anti- FCER1A...
...compared with an isotype control, whereas adoptive transfer of MMC9s from untreated models to the anti-FCER1A...
...TARGET/MARKER/PATHWAY: Interleukin-9 (IL-9) ; Fc fragment of IgE high affinity I receptor for α polypeptide (FCER1A...
BioCentury | Dec 12, 2013
Cover Story

T cells go universal

National University of Singapore and St. Jude Children's Research Hospital team has engineered a T cell therapeutic that can engage in antibody-dependent cell cytotoxicity and enhance the effects of therapeutic antibodies regardless of the target...
Items per page:
1 - 7 of 7